Connect to other sites within the UBM Medica Network
Role for Ibrutinib Confirmed in Relapsed/Refractory 17p Deletion CLL
Phase II data provide further evidence that patients with relapsed/refractory chronic lymphocytic leukemia with 17p deletion have a new treatment option with ibrutinib.
Benefits of Colon Cancer Screening Decrease After Age 75
Colonoscopy screening is modestly effective for preventing colorectal cancer in patients aged 70 to 74, but the benefits may begin to diminish after that.
FDA Announces Nivolumab Dose Change for RCC, NSCLC, Metastatic Melanoma
The FDA announced a modification to the recommended dosage regimen for nivolumab (Opdivo) for renal cell carcinoma (RCC), metastatic melanoma, and non–small-cell lung cancer (NSCLC).
Higher RT Dose in Pediatric Brain Tumors Limited Vocabulary Development
In children with primary brain tumors who were treated with cranial radiation, cerebral volume and radiation dose may affect the rate of vocabulary development.
Realities of Phase I Clinical Trials May Not Match Patient Expectations
More than 80% of patients referred for consideration in a phase I clinical trial were still willing to participate after a consultation where they learned more about trial participation.
PI3K, HDAC Inhibition With CUDC-907 Shows Promise in Thyroid Cancer
Dual inhibition of PI3K signaling and histone deacetylase 2 (HDAC2) enzymes with CUDC-907 slowed thyroid tumor cell proliferation, tumor progression and metastasis, according to a preclinical study.
Immunotherapy Patients Should Be Monitored for Destructive Thyroiditis
The risk of immunotherapy-related destructive thyroiditis requires close patient monitoring and can cause permanent hypothyroidism.
Ibrutinib Improves on Standard of Care in CLL/SLL
A trial found that ibrutinib in combination with bendamustine and rituximab is superior to standard of care in patients with previously treated CLL/SLL.
Adjuvant Chemo Ups Survival in High-Risk Localized Prostate Cancer
The addition of docetaxel and prednisone to standard therapy may be the first effective adjuvant chemotherapy treatment for high-risk prostate cancer patients.
Palbociclib, Fulvestrant Delays HR-Positive Breast Cancer Progression
The addition of palbociclib to fulvestrant delayed disease progression in women with HR-positive, HER2-negative metastatic breast cancer.
Anastrozole Trumps Tamoxifen in DCIS
Treatment of postmenopausal DCIS patients with the aromatase inhibitor anastrozole resulted in higher breast cancer–free survival rates compared with treatment with tamoxifen.
November 2015 News Roundup
In this November news roundup we highlight some of the top stories of the month, including several FDA approvals, new breast cancer guidelines, and more.
By clicking Accept, you agree to become a member of the UBM Medica Community.